List of Cysview Kit drug patents
Cysview Kit is owned by Photocure Asa.
Cysview Kit contains Hexaminolevulinate Hydrochloride.
Cysview Kit has a total of 3 drug patents out of which 0 drug patents have expired.
Cysview Kit was authorised for market use on 28 May, 2010.
Cysview Kit is available in for solution;intravesical dosage forms.
Cysview Kit can be used as detection of carcinoma in the bladder by photodynamic cystoscopy.
The generics of Cysview Kit are possible to be released after 04 January, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10556010 | PHOTOCURE ASA | Neoadjuvant therapy for bladder cancer |
Dec, 2036
(13 years from now) | |
| US11311620 | PHOTOCURE ASA | Neoadjuvant therapy for bladder cancer |
Dec, 2036
(13 years from now) | |
| US11235168 | PHOTOCURE ASA | Method of photodynamic therapy (PDT) for bladder cancer |
Jan, 2038
(14 years from now) | |
Drugs and Companies using HEXAMINOLEVULINATE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 2010
Treatment: Detection of carcinoma in the bladder by photodynamic cystoscopy
Dosage: FOR SOLUTION;INTRAVESICAL
CYSVIEW KIT family patents
5
United States
5
European Union
2
Russia
2
Japan
2
Brazil
2
Canada
2
Australia
2
Korea, Republic of
2
China
1
Israel
1
Singapore
1
South Africa
1
Denmark
1
Spain
1
Poland
1
United Kingdom
1
Chile
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic